share_log

Further Weakness as Hainan Haiyao (SZSE:000566) Drops 7.7% This Week, Taking Three-year Losses to 51%

Further Weakness as Hainan Haiyao (SZSE:000566) Drops 7.7% This Week, Taking Three-year Losses to 51%

海南海药(深交所股票代码:000566)本周下跌7.7%,使三年跌幅达到51%,进一步疲软
Simply Wall St ·  2023/12/20 17:05

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long term Hainan Haiyao Co., Ltd. (SZSE:000566) shareholders know that all too well, since the share price is down considerably over three years. Regrettably, they have had to cope with a 51% drop in the share price over that period. On top of that, the share price is down 7.7% in the last week.

如果你正在建立一个适当多元化的股票投资组合,那么你的某些选择很可能会表现不佳。从长远来看,海南海药股份有限公司(深交所股票代码:000566)的股东对此非常了解,因为股价在三年内大幅下跌。遗憾的是,在此期间,他们不得不应对股价下跌51%的局面。最重要的是,上周股价下跌了7.7%。

Since Hainan Haiyao has shed CN¥493m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由于海南海药在过去7天内贬值了4.93亿元人民币,让我们看看长期下跌是否是由该企业的经济推动的。

See our latest analysis for Hainan Haiyao

查看我们对海南海药的最新分析

Given that Hainan Haiyao only made minimal earnings in the last twelve months, we'll focus on revenue to gauge its business development. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.

鉴于海南海药在过去十二个月中仅实现了最低收益,我们将重点关注收入来衡量其业务发展。总的来说,我们会将这样的股票与亏损公司一起考虑,这仅仅是因为利润量太低了。要使股东有信心公司大幅增加利润,就必须增加收入。

In the last three years Hainan Haiyao saw its revenue shrink by 11% per year. That is not a good result. With revenue in decline, and profit but a dream, we can understand why the share price has been declining at 15% per year. Having said that, if growth is coming in the future, now may be the low ebb for the company. We'd be pretty wary of this one until it makes a profit, because we don't specialize in finding turnaround situations.

在过去的三年中,海南海药的收入每年减少11%。这不是一个好结果。收入下降,利润只是梦想,我们可以理解为什么股价每年下跌15%。话虽如此,如果未来出现增长,那么现在可能是公司的低潮。在它盈利之前,我们会非常警惕,因为我们不擅长寻找转机情况。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下图描述了收入和收入随时间推移而发生的变化(点击图片即可显示确切的数值)。

earnings-and-revenue-growth
SZSE:000566 Earnings and Revenue Growth December 20th 2023
SZSE: 000566 2023年12月20日收益和收入增长

This free interactive report on Hainan Haiyao's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想进一步调查海南海药资产负债表实力,这份关于海南海药资产负债表实力的免费互动报告是一个很好的起点。

A Different Perspective

不同的视角

It's good to see that Hainan Haiyao has rewarded shareholders with a total shareholder return of 0.7% in the last twelve months. That certainly beats the loss of about 2% per year over the last half decade. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 1 warning sign for Hainan Haiyao that you should be aware of before investing here.

很高兴看到海南海药在过去十二个月中向股东提供了0.7%的总股东回报率。这无疑超过了过去五年中每年约2%的损失。我们通常更看重短期内的长期表现,但最近的改善可能暗示业务出现了(积极的)转折点。尽管市场状况可能对股价产生的不同影响值得考虑,但还有其他因素更为重要。例如,我们发现了海南海药的1个警告信号,在这里投资之前你应该注意这个信号。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果你想看看另一家公司——一家财务状况可能优异的公司——那么千万不要错过这份已经证明自己可以增加收益的公司的免费名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发